Floatz logo

FILGRASTIM

Hyper IgM Syndrome

Masonic Cancer Center, University of Minnesotaprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Hyper IgM Syndrome cohort.

Asset / SponsorPhaseRating
Evomela
Washington University School of Medicine
Phase 2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Washington University School of Medicine
Phase 2CCC
Fludarabine
Washington University School of Medicine
Phase 2CCC
Romidepsin
Masonic Cancer Center, University of Minnesota
N/AD
Busulphan
Masonic Cancer Center, University of Minnesota
N/AD
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
N/AD
Mesna
Masonic Cancer Center, University of Minnesota
N/AD

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →